{"id":"eylea-aflibercept","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Conjunctival hemorrhage"},{"rate":"10-15","effect":"Eye pain"},{"rate":"10-15","effect":"Floaters"},{"rate":"5-10","effect":"Intraocular pressure elevation"},{"rate":"<1","effect":"Endophthalmitis"},{"rate":"<1","effect":"Retinal detachment"}]},"_chembl":{"chemblId":"CHEMBL1742982","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept functions as a fusion protein combining VEGF-binding domains from VEGF receptors 1 and 2 with the Fc portion of human IgG1. By sequestering circulating VEGF and PlGF, it prevents these growth factors from activating their endogenous receptors on endothelial cells, thereby reducing pathological neovascularization and vascular permeability in retinal diseases. This mechanism is particularly effective in wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion.","oneSentence":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:34.639Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Wet age-related macular degeneration (wAMD)"},{"name":"Diabetic macular edema (DME)"},{"name":"Macular edema following retinal vein occlusion (RVO)"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT07496567","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-04-30","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT06864988","phase":"PHASE3","title":"4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"ACTIVE_NOT_RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-03-03","conditions":"Macular Neovascularization Secondary to Age-Related Macular Degeneration","enrollment":480},{"nctId":"NCT07489586","phase":"PHASE3","title":"A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2026-03","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":356},{"nctId":"NCT07440225","phase":"PHASE2, PHASE3","title":"A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)","status":"NOT_YET_RECRUITING","sponsor":"EyeBiotech Ltd.","startDate":"2026-03-31","conditions":"Macular Degeneration, Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":960},{"nctId":"NCT07064759","phase":"PHASE3","title":"Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"4D Molecular Therapeutics","startDate":"2025-07-22","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":480},{"nctId":"NCT06321302","phase":"PHASE2","title":"A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2024-05-15","conditions":"Diabetic Retinopathy","enrollment":178},{"nctId":"NCT07235527","phase":"","title":"Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration","status":"RECRUITING","sponsor":"Saglik Bilimleri Universitesi","startDate":"2025-11-20","conditions":"Age Related Macular Degeneration, Exudative Age-Related Macular Degeneration, Anti Vascular Endothelial Growth Factor","enrollment":54},{"nctId":"NCT04932980","phase":"NA","title":"Comparison of Rapid Aflibercept and Brolucizumab T&E in wAMD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Berner Augenklinik","startDate":"2022-05-09","conditions":"Wet Age-related Macular Degeneration","enrollment":80},{"nctId":"NCT04522167","phase":"PHASE3","title":"Efficacy and Safety of the Aflibercept FYB203 Biosimilar in Comparison to Eylea® in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Bioeq GmbH","startDate":"2020-07-21","conditions":"Neovascular Age-related Macular Degeneration","enrollment":434},{"nctId":"NCT06769412","phase":"","title":"A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-07-01","conditions":"Retinal Vasculitis","enrollment":550000},{"nctId":"NCT06491914","phase":"PHASE3","title":"A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-07-24","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":1118},{"nctId":"NCT07105228","phase":"","title":"Incidence of Retinal Vasculitis Among Patients Receiving Aflibercept: A US Real-World Evidence Study","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2025-07-15","conditions":"Retinal Vasculitis","enrollment":290000},{"nctId":"NCT05407636","phase":"PHASE3","title":"Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD","status":"RECRUITING","sponsor":"AbbVie","startDate":"2022-01-13","conditions":"AMD, nAMD, Wet Age-related Macular Degeneration","enrollment":660},{"nctId":"NCT00532155","phase":"PHASE3","title":"A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-09","conditions":"Carcinoma, Non Small Cell Lung","enrollment":913},{"nctId":"NCT04270747","phase":"PHASE3","title":"A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]","status":"COMPLETED","sponsor":"Amgen","startDate":"2020-06-22","conditions":"Neovascular (Wet) Age-related Macular Degeneration (AMD)","enrollment":576},{"nctId":"NCT07129239","phase":"PHASE3","title":"High Dose (HD) Aflibercept Switch in Neovascular Age-related Macular Degeneration (nAMD): to Load or Maintain (HEIRLOOM)","status":"NOT_YET_RECRUITING","sponsor":"Clinique de Retine de l'est","startDate":"2025-08-20","conditions":"Wet Age-related Macular Degeneration (wAMD)","enrollment":180},{"nctId":"NCT04429503","phase":"PHASE2, PHASE3","title":"Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2020-06-29","conditions":"Diabetic Macular Edema, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus","enrollment":660},{"nctId":"NCT05941715","phase":"PHASE4","title":"Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2023-07-04","conditions":"Neovascular Age-related Macular Degeneration","enrollment":70},{"nctId":"NCT05989126","phase":"PHASE3","title":"Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-04-15","conditions":"Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":35},{"nctId":"NCT06470373","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"Rophibio, Inc.","startDate":"2025-07","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":434},{"nctId":"NCT02397954","phase":"PHASE2","title":"A Study to Establish the Safety and Tolerability of Zimura™ (Anti-C5 Aptamer) in Combination With Anti-VEGF Therapy in Subjects With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"COMPLETED","sponsor":"Ophthotech Corporation","startDate":"2015-03-12","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":4},{"nctId":"NCT05704725","phase":"PHASE3","title":"A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)","status":"COMPLETED","sponsor":"Amgen","startDate":"2023-01-23","conditions":"Chorioretinal Vascular Disease","enrollment":49},{"nctId":"NCT06132035","phase":"PHASE1","title":"Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration","status":"RECRUITING","sponsor":"Caregen Co. Ltd.","startDate":"2023-12-22","conditions":"Age-related Wet Macular Degeneration","enrollment":45},{"nctId":"NCT05178745","phase":"","title":"Resection Observatory","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-09-07","conditions":"Metastatic Colorectal Cancer, Colorectal Neoplasms","enrollment":140},{"nctId":"NCT06610747","phase":"NA","title":"Home- vs Hospital-based Care of Anti-VEGF Treatment for Diabetic Macular Edema: Non-inferiority RCT","status":"RECRUITING","sponsor":"Zhongshan Ophthalmic Center, Sun Yat-sen University","startDate":"2024-10-28","conditions":"Diabetic Macular Edema","enrollment":308},{"nctId":"NCT02434328","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-07-28","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1048},{"nctId":"NCT02307682","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-12-08","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1775},{"nctId":"NCT06398080","phase":"","title":"An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting","status":"WITHDRAWN","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-12-12","conditions":"Neovascular Age-related Macular Degeneration (nAMD), Wet Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME)","enrollment":""},{"nctId":"NCT01940887","phase":"PHASE3","title":"A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-05","conditions":"Age-Related Macular Degeneration","enrollment":645},{"nctId":"NCT02387957","phase":"PHASE2","title":"A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2016-04-26","conditions":"Age-Related Macular Degeneration","enrollment":63},{"nctId":"NCT05155293","phase":"PHASE3","title":"Clinical Study to Compare Efficacy and Safety of AVT06 and EU-Eylea (ALVOEYE)","status":"COMPLETED","sponsor":"Alvotech Swiss AG","startDate":"2022-06-28","conditions":"Neovascular (Wet) AMD","enrollment":413},{"nctId":"NCT05275205","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy Study of UBX1325 in Patients With Neovascular Age-Related Macular Degeneration (ENVISION)","status":"COMPLETED","sponsor":"Unity Biotechnology, Inc.","startDate":"2022-03-02","conditions":"Neovascular Age-related Macular Degeneration","enrollment":51},{"nctId":"NCT04740905","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Macular Edema, Branch Retinal Vein Occlusion","enrollment":553},{"nctId":"NCT04740931","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-03-02","conditions":"Macular Edema, Central Retinal Vein Occlusion, Hemiretinal Vein Occlusion","enrollment":729},{"nctId":"NCT04469595","phase":"PHASE4","title":"A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alimera Sciences","startDate":"2020-08-31","conditions":"Diabetic Macular Edema","enrollment":300},{"nctId":"NCT04864834","phase":"PHASE3","title":"Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Sandoz","startDate":"2021-05-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":485},{"nctId":"NCT02214628","phase":"PHASE2","title":"Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF BB) Regimen Administered in Combination With Anti-VEGF Therapy to Study Sub-Retinal Fibrosis in Neovascular AMD","status":"TERMINATED","sponsor":"Ophthotech Corporation","startDate":"2014-07","conditions":"Age-related Macular Degeneration","enrollment":101},{"nctId":"NCT03374670","phase":"PHASE2","title":"ZIMURA in Combination With Eylea in Patients With Idiopathic Polypoidal Choroidal Vasculopathy (IPCV)","status":"WITHDRAWN","sponsor":"Ophthotech Corporation","startDate":"2018-11","conditions":"Idiopathic Polypoidal Choroidal Vasculopathy","enrollment":""},{"nctId":"NCT04450329","phase":"PHASE3","title":"A Study to Compare SB15 (Proposed Aflibercept Biosimilar) to Eylea in Subjects With Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2020-06-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":449},{"nctId":"NCT02289924","phase":"","title":"Aflibercept (Eylea) in roUtine Clinical Practice in patientS With Wet Age-related Macular Degeneration in Italy","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-01-09","conditions":"Wet Macular Degeneration","enrollment":912},{"nctId":"NCT04480463","phase":"PHASE3","title":"A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Sam Chun Dang Pharm. Co. Ltd.","startDate":"2020-08-13","conditions":"Wet Age-related Macular Degeneration, Neovascular Age-related Macular Degeneration","enrollment":576},{"nctId":"NCT05063734","phase":"PHASE2","title":"A Study to Evaluate THR-687 Treatment for Diabetic Macular Oedema.","status":"TERMINATED","sponsor":"Oxurion","startDate":"2021-08-27","conditions":"Diabetes Mellitus, Diabetic Retinopathy, Diabetic Macular Edema","enrollment":16},{"nctId":"NCT04126317","phase":"PHASE2","title":"Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-11-04","conditions":"Neovascular (Wet) Age-Related Macular Degeneration","enrollment":106},{"nctId":"NCT04101721","phase":"PHASE3","title":"Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2019-10-30","conditions":"Retinopathy of Prematurity","enrollment":127},{"nctId":"NCT04200248","phase":"PHASE2","title":"A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Ribomic USA Inc","startDate":"2019-12-02","conditions":"Exudative Age-related Macular Degeneration","enrollment":94},{"nctId":"NCT03610646","phase":"PHASE3","title":"Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2018-08-23","conditions":"Diabetic Macular Edema","enrollment":355},{"nctId":"NCT04137120","phase":"","title":"Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-02-19","conditions":"Retinal Disease","enrollment":73},{"nctId":"NCT05587062","phase":"PHASE3","title":"Efficacy and Safety of Aflibercept in Patients With Neovascular Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Cinnagen","startDate":"2019-10-01","conditions":"Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration","enrollment":168},{"nctId":"NCT03802630","phase":"PHASE3","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-02","conditions":"Branch Retinal Vein Occlusion","enrollment":450},{"nctId":"NCT03810313","phase":"PHASE3","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-03","conditions":"Central Retinal Vein Occlusion","enrollment":493},{"nctId":"NCT02228304","phase":"PHASE1, PHASE2","title":"Study of the Intravitreal Implantation of NT-503-3 Encapsulated Cell Technology (ECT) for the Treatment of Recurrent Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Neurotech Pharmaceuticals","startDate":"2014-09","conditions":"Macular Degeneration","enrollment":42},{"nctId":"NCT04641234","phase":"","title":"A Study Reviewing Medical Records to Learn More About Treat-and-extend With Eylea in Patients With Neovascular Age-related Macular Degeneration (nAMD).","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-12-11","conditions":"Neovascular Age-related Macular Degeneration","enrollment":330},{"nctId":"NCT02432547","phase":"PHASE4","title":"Laser Therapy Combined With Intravitreal Aflibercept vs Intravitreal Aflibercept Monotherapy (LADAMO)","status":"COMPLETED","sponsor":"University of Sydney","startDate":"2017-06-15","conditions":"Diabetic Retinopathy","enrollment":48},{"nctId":"NCT05345236","phase":"PHASE3","title":"A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2019-08-19","conditions":"Wet Age-related Macular Degeneration","enrollment":366},{"nctId":"NCT04919096","phase":"PHASE1","title":"Study of SCB-420 in Subjects With Neovascular Age-related Macular Degeneration","status":"WITHDRAWN","sponsor":"Clover Biopharmaceuticals AUS Pty","startDate":"2022-04","conditions":"Wet Age-related Macular Degeneration","enrollment":""},{"nctId":"NCT05324774","phase":"PHASE3","title":"Efficacy and Safety of 9MW0813 in Subjects With Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2022-02-28","conditions":"Diabetic Macular Edema","enrollment":346},{"nctId":"NCT05324592","phase":"PHASE1","title":"Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","startDate":"2021-02-26","conditions":"Diabetic Macular Edema","enrollment":24},{"nctId":"NCT05282420","phase":"PHASE4","title":"Ranibizumab Versus Aflibercept for CRVO in Young Patients.","status":"UNKNOWN","sponsor":"South Valley University","startDate":"2021-02-01","conditions":"Non-Ischemic Central Retinal Vein Occlusion With Macular Edema","enrollment":40},{"nctId":"NCT04891835","phase":"","title":"Analysis of naïve Patients With Age-related Macular Degeneration of the Neovascular Type and Treated With Aflibercept (Eylea®) in \"Treat-and-extend\" at CHU Brugmann","status":"COMPLETED","sponsor":"Laurence Postelmans","startDate":"2021-04-13","conditions":"Age-related Macular Degeneration","enrollment":36},{"nctId":"NCT05110209","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":331541},{"nctId":"NCT05146687","phase":"","title":"Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Age-related Macular Degeneration (AMD) Who Received Anti-vascular Endothelial Growth Factor (VEGF) Agents (Komodo Health)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2020-07-15","conditions":"Age-related Macular Degeneration (AMD)","enrollment":369600},{"nctId":"NCT03767738","phase":"PHASE4","title":"Study to Evaluate an Aflibercept (EYLEA®) Prefilled Syringe","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2018-12-19","conditions":"Chorioretinal Vascular Disease","enrollment":65},{"nctId":"NCT03577899","phase":"PHASE3","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)","status":"TERMINATED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2018-09-25","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1157},{"nctId":"NCT03630952","phase":"PHASE3","title":"Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2)","status":"TERMINATED","sponsor":"Chengdu Kanghong Biotech Co., Ltd.","startDate":"2018-12-21","conditions":"Neovascular Age-related Macular Degeneration","enrollment":1157},{"nctId":"NCT03452527","phase":"PHASE2","title":"Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Iconic Therapeutics, Inc.","startDate":"2018-03-26","conditions":"Choroidal Neovascularization, Wet Macular Degeneration","enrollment":15},{"nctId":"NCT02418754","phase":"PHASE2","title":"Study of Intravitreal REGN2176-3 in Participants With Neovascular (\"Wet\") Age-Related Macular Degeneration (AMD)","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2015-05-05","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":505},{"nctId":"NCT02718326","phase":"PHASE3","title":"Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-03-29","conditions":"Nonproliferative Diabetic Retinopathy","enrollment":402},{"nctId":"NCT03629210","phase":"PHASE2","title":"Combination OZURDEX® & EyLea® vs. OZURDEX® Monotherapy in IncompLete-Responders wIth Diabetic Macular Edema","status":"WITHDRAWN","sponsor":"Pradeepa Yoganathan","startDate":"2019-09","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT02797704","phase":"PHASE1, PHASE2","title":"Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization","status":"TERMINATED","sponsor":"Rabin Medical Center","startDate":"2017-03-02","conditions":"Corneal Neovascularization","enrollment":6},{"nctId":"NCT02713204","phase":"PHASE2","title":"Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-03-31","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":365},{"nctId":"NCT01918371","phase":"","title":"A Retrospective Study of Anti-Vascular Endothelial Growth Factor (VEGF) Injections for Retinal Vein Occlusion or Diabetic Macular Edema","status":"COMPLETED","sponsor":"Allergan","startDate":"2013-08-02","conditions":"Retinal Vein Occlusion, Macular Edema","enrollment":323},{"nctId":"NCT01958918","phase":"PHASE4","title":"Efficacy of Ranibizumab Prn Treatment Compared to Aflibercept Bimonthly Intravitreal Injections on Retinal Thickness Stability in Patients With Wet AMD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10-23","conditions":"Neovascular Age-related Macular Degeneration","enrollment":712},{"nctId":"NCT02554747","phase":"NA","title":"Aflibercept anD navigateD vErsus coNvensional Laser in Diabetic macUlar edeMa","status":"COMPLETED","sponsor":"Odense University Hospital","startDate":"2015-10","conditions":"Diabetic Macular Oedema","enrollment":48},{"nctId":"NCT02320474","phase":"PHASE4","title":"Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)","status":"COMPLETED","sponsor":"Poitiers University Hospital","startDate":"2014-11-25","conditions":"Type 3 Choroidal Neovascularization","enrollment":26},{"nctId":"NCT03783832","phase":"","title":"Follow up of Diabetic Macular Edema Treated by Aflibercept (Eylea®) With OCT-Angiography","status":"UNKNOWN","sponsor":"Aquitania Opthalmologica","startDate":"2018-06-19","conditions":"Diabetic Macular Edema","enrollment":48},{"nctId":"NCT02712008","phase":"PHASE2","title":"Anti-vasculaR Endothelial Growth Factor plUs Anti-angiopoietin 2 in Fixed comBination therapY: Evaluation for the Treatment of Diabetic Macular Edema","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2016-03-02","conditions":"Diabetic Macular Edema","enrollment":302},{"nctId":"NCT02591914","phase":"PHASE1","title":"An Open-Label Investigator Sponsored Trial to Investigate the Safety, Tolerability and Development of Subfoveal Fibrosis By Intravitreal Administration of Altering Regimens of Fovista and Anti-VEGF Therapy in Subjects With Neovascular Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Retinal Consultants of Arizona","startDate":"2014-02","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":30},{"nctId":"NCT03468296","phase":"PHASE4","title":"Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept","status":"UNKNOWN","sponsor":"Tennessee Retina","startDate":"2018-04","conditions":"Neovascular Age-related Macular Degeneration","enrollment":22},{"nctId":"NCT02401945","phase":"PHASE2","title":"A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2015-04","conditions":"Age-Related Macular Degeneration","enrollment":16},{"nctId":"NCT01914380","phase":"","title":"Investigating the Effectiveness of Eylea in Patients With Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-07-29","conditions":"Wet Age-related Macular Degeneration","enrollment":988},{"nctId":"NCT02732899","phase":"PHASE2","title":"Sirolimus in Conjunction With Eylea vs Eylea Alone for Exudative AMD","status":"COMPLETED","sponsor":"Maturi, Raj K., M.D., P.C.","startDate":"2016-04","conditions":"Exudative Age Related Macular Degeneration","enrollment":20},{"nctId":"NCT02924987","phase":"PHASE4","title":"Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema","status":"UNKNOWN","sponsor":"Maisonneuve-Rosemont Hospital","startDate":"2016-11","conditions":"Diabetic Macular Edema","enrollment":40},{"nctId":"NCT02246829","phase":"PHASE4","title":"Assessment of Early Changes in SD-OCT After Initiation of a Treatment by Intravitreal Aflibercept (EYLEA®)START","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2014-09","conditions":"Neovascular Age-related Macular Degeneration of All Subtypes","enrollment":50},{"nctId":"NCT00519285","phase":"PHASE3","title":"Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-08","conditions":"Prostatic Neoplasms, Neoplasm Metastasis","enrollment":1224},{"nctId":"NCT00574275","phase":"PHASE3","title":"Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Sanofi","startDate":"2007-12","conditions":"Pancreatic Neoplasm","enrollment":546},{"nctId":"NCT00327171","phase":"PHASE2","title":"Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-05","conditions":"Neoplasms, Cancer of the Ovary","enrollment":218},{"nctId":"NCT01363440","phase":"PHASE3","title":"Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Patients With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2011-05","conditions":"Diabetic Macular Edema","enrollment":466},{"nctId":"NCT01796964","phase":"PHASE2","title":"Efficacy and Safety Study of ESBA1008 Versus EYLEA®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-03","conditions":"Exudative Age-Related Macular Degeneration","enrollment":173},{"nctId":"NCT01997164","phase":"PHASE1","title":"Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (\"Wet\") Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-11","conditions":"Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema","enrollment":20},{"nctId":"NCT01868360","phase":"PHASE1","title":"Using Aflibercept Injection to Treat Blood Vessel Growth Over the Cornea","status":"TERMINATED","sponsor":"Balamurali Ambati","startDate":"2013-06","conditions":"Corneal Neovascularization","enrollment":2},{"nctId":"NCT00964795","phase":"PHASE3","title":"Open-label Extension Study of Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321) in Neovascular (\"Wet\") Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2009-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":323},{"nctId":"NCT01521559","phase":"PHASE3","title":"Study to Assess the Clinical Efficacy and Safety of Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321) in Patients With Branch Retinal Vein Occlusion (BRVO)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2012-04","conditions":"Branch Retinal Vein Occlusion","enrollment":183},{"nctId":"NCT00789477","phase":"PHASE2","title":"DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2008-12","conditions":"Diabetic Macular Edema","enrollment":221},{"nctId":"NCT00396591","phase":"PHASE2","title":"AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-10","conditions":"Ovarian Neoplasms","enrollment":16},{"nctId":"NCT00327444","phase":"PHASE2, PHASE3","title":"Study of the Effect of Intravenous AVE0005 (VEGF Trap) in Advanced Ovarian Cancer Patients With Recurrent Symptomatic Malignant Ascites","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-07","conditions":"Ovarian Neoplasms, Ascites","enrollment":58},{"nctId":"NCT00284141","phase":"PHASE2","title":"Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-01","conditions":"Pulmonary Diseases, Neoplasms, Lung","enrollment":98},{"nctId":"NCT00561470","phase":"PHASE3","title":"Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-11","conditions":"Colorectal Neoplasms, Neoplasm Metastasis","enrollment":1226}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4094,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Eylea® (Aflibercept)","genericName":"Eylea® (Aflibercept)","companyName":"Alvotech Swiss AG","companyId":"alvotech-swiss-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Aflibercept is a soluble decoy receptor that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye. Used for Wet age-related macular degeneration (wAMD), Diabetic macular edema (DME), Macular edema following retinal vein occlusion (RVO).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}